H
Henry E. Holden
Researcher at Pfizer
Publications - 14
Citations - 734
Henry E. Holden is an academic researcher from Pfizer. The author has contributed to research in topics: In vivo & Chromosome breakage. The author has an hindex of 9, co-authored 14 publications receiving 715 citations.
Papers
More filters
Journal ArticleDOI
Mammalian in vivo cytogenetic assays. Analysis of chromosome aberrations in bone marrow cells.
Journal ArticleDOI
Comparison of somatic and germ cell models for cytogenetic screening
TL;DR: It is suggested that a negative somatic‐cell response can be taken as highly predictive of negative results in a germ cell assessment and an inherent relative insensitivity of germ cells themselves to mutagenic chemicals is suggested.
Journal ArticleDOI
Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction.
Henry E. Holden,John F. Barett,Channing M. Huntington,Paula A. Muehlbauer,Margitta G. Wahrenburg +4 more
TL;DR: An analog of nalidixic acid with potent topoisomerase II inhibitory activity was selected for examination and proved to be a positive direct‐acting mutagen in the L5178Y/TK+/‐, CHO/ HGPRT, and V79/HGPRT systems.
Journal ArticleDOI
Mutagenicity studies with 6-mercaptopurine: I. Cytogenetic activity in vivo
TL;DR: Cytogenetic studies have been performed to determine the effect of 6-mercaptopurine on mammalian chromosomes in vivo and an elevated level of chromosome breakage is present in mouse bone marrow cells within 12 h after oral or parenteral dosing with 200 mg/kg.
Journal ArticleDOI
Mitotic arrest by benzimidazole analogs in human lymphocyte cultures
TL;DR: Investigation of the possible association of mutagenic or teratogenic properties of some benzimidazole analogs with induced spindle disruption and consequent mitotic arrest found some utility of mitotic assessments for predicting teratogenicity.